91 related articles for article (PubMed ID: 10928043)
1. Chemosensitivity testing of irinotecan (CPT-11) in ovarian and endometrial carcinomas: a comparison with cisplatin.
Koshiyama M; Fujii H; Kinezaki M; Ohgi S; Konishi M; Hidetaka N; Hayashi M; Yoshida M
Anticancer Res; 2000; 20(3A):1353-8. PubMed ID: 10928043
[TBL] [Abstract][Full Text] [Related]
2. Chemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin.
Koshiyama M; Kinezaki M; Uchida T; Sumitomo M
Anticancer Res; 2005; 25(6C):4499-502. PubMed ID: 16334133
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
4. In vitro sensitivity of human endometrial cancer cell lines to paclitaxel or irinotecan (CPT-11) in combination with other aniticancer drugs.
Hiramatsu HP; Kikuchi Y; Seto H; Nagata I
Anticancer Drugs; 2000 Aug; 11(7):573-8. PubMed ID: 11036961
[TBL] [Abstract][Full Text] [Related]
5. Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Yoshida M
Anticancer Res; 2001; 21(2A):905-10. PubMed ID: 11396183
[TBL] [Abstract][Full Text] [Related]
6. Chemosensitivity testing of paclitaxel versus docetaxel in human gynecological carcinomas: a comparison with carboplatin.
Koshiyama M; Kinezaki M; Uchida T; Sumitomo M
Anticancer Res; 2006; 26(5B):3655-9. PubMed ID: 17094381
[TBL] [Abstract][Full Text] [Related]
7. [The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line].
Shi W; Gu M; Liang L
Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):79-82. PubMed ID: 8758798
[TBL] [Abstract][Full Text] [Related]
8. [Preclinical evaluation of a new camptothecin derivative, CPT-11, on the subrenal capsule assay].
Wang Y; Inoue K; Shibata H; Itoh Y; Chen SC; Ogawa M
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 1):1264-7. PubMed ID: 3579325
[TBL] [Abstract][Full Text] [Related]
9. In vitro sensitivity of fresh ovarian carcinoma specimens to CPT-11 (irinotecan).
O'meara AT; Sevin BU
Gynecol Oncol; 1999 Feb; 72(2):143-7. PubMed ID: 10021292
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of collagen gel droplet embedded culture drug sensitivity testing in ovarian cancer.
Yabushita H; Ohnishi M; Komiyama M; Mori T; Noguchi M; Kishida T; Noguchi Y; Sawaguchi K; Noguchi M
Oncol Rep; 2004 Aug; 12(2):307-11. PubMed ID: 15254694
[TBL] [Abstract][Full Text] [Related]
11. Endometrial cancer cell lines are sensitive to paclitaxel.
Rantanen V; Grénman S; Kulmala J; Grénman R
Anticancer Res; 1996; 16(1):475-9. PubMed ID: 8615657
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response.
Nakada S; Aoki D; Ohie S; Horiuchi M; Suzuki N; Kanasugi M; Susumu N; Udagawa Y; Nozawa S
Int J Gynecol Cancer; 2005; 15(3):445-52. PubMed ID: 15882168
[TBL] [Abstract][Full Text] [Related]
13. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a CPT-11-resistant human ovarian cancer cell line.
Kijima T; Kubota N; Nishio K
Anticancer Res; 1994; 14(3A):799-803. PubMed ID: 8074481
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes.
Cohen DP; Adams DJ; Flowers JL; Wall ME; Wani MC; Manikumar G; Colvin OM; Silber R
Leuk Res; 1999 Nov; 23(11):1061-70. PubMed ID: 10576512
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
Romanelli S; Perego P; Pratesi G; Carenini N; Tortoreto M; Zunino F
Cancer Chemother Pharmacol; 1998; 41(5):385-90. PubMed ID: 9523734
[TBL] [Abstract][Full Text] [Related]
17. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic agents active against mucinous adenocarcinoma of the ovary.
Shimizu Y; Nagata H; Kikuchi Y; Umezawa S; Hasumi K; Yokokura T
Oncol Rep; 1998; 5(1):99-101. PubMed ID: 9458301
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
O'Meara AT; Sevin BU
Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
[TBL] [Abstract][Full Text] [Related]
20. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]